Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

Sep 12 2018

• By Mandy Jackson

pills

Related Content

Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach

Oct 03 2017

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

Jun 02 2018

Ilumya Becomes Sun's New Branded Specialty Drug Pillar

Mar 21 2018

Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications

Jul 27 2018

Related Companies

Bristol Myers Squibb Company

Pfizer Inc.

Incyte Corporation

Eli Lilly and Company

Johnson & Johnson

Sun Pharmaceutical Industries Ltd.

Nimbus Therapeutics, Inc.

Bristol Myers Squibb Company

Galapagos NV

SRI International

Vividion Therapeutics, Inc.

Additional Topics

Clinical Trials Drug Safety Research & Development Immune Disorders Inflammation BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.